Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma | NEJM – nejm.org

by

  1. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma | NEJM nejm.org
  2. ESMO 2023: LITESPARK-005 Belzutifan Versus Everolimus in Participants with Previously Treated Advanced Clear Cell Renal Cell Carcinoma: Randomized Open-Label Phase 3 UroToday
  3. ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes Yahoo Finance
  4. At ESMO, Merck touts Welireg’s potential in kidney cancer FiercePharma
  5. ESMO 2023: STELLAR-304: A Randomized Phase 3 Study of Zanzalintinib (XL092) and Nivolumab in Non-Clear Cell Renal Cell Carcinoma UroToday
  6. View Full Coverage on Google News

Read original article here

Leave a Comment